Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Mesenchymal stromal cell apoptosis is required for their therapeutic function

ABSTRACT: Mesenchymal stromal cell apoptosis is required for their therapeutic function

PROVIDER: PRJNA657172 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR12453546.fastq.gz	Fastqsanger.gz
	SRR12453547.fastq.gz	Fastqsanger.gz
	SRR12453548.fastq.gz	Fastqsanger.gz
	SRR12453549.fastq.gz	Fastqsanger.gz
	SRR12453550.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 16

Similar Datasets

Mesenchymal stromal cell apoptosis is required for their therapeutic function

Project description:The demonstration that mesenchymal stromal cells (MSCs) can ameliorate a wide range of diseases in preclinical models has led to many clinical trials investigating their use as a treatment modality. Their therapeutic effects are often attributed to their secretome, a proposition predicated on their long-term survival. However, the majority of MSCs do not survive in vivo administration. We sought to reconcile the immunosuppressive effects of MSC therapy with their short lifespan. We showed that almost all MSCs underwent apoptosis associated with caspase-3 activation within 1 hour of intravenous administration and were efferocytosed by lung phagocytes. The potent immunosuppressive effects of MSCs did not require them to remain viable, but instead involved efferocytosis-induced transcriptional changes in metabolic and inflammatory pathways in alveolar macrophages. We identified the mitochondrial pathway as the predominant mechanism involved in MSC apoptosis, as deletion of the effectors BAK/BAX prevented their death. Importantly, BAK/BAX deficiency in MSCs weakened their immunosuppressive effects in 2 different disease models used to define MSC potency. Our data showed that apoptosis of MSCs and their subsequent efferocytosis and macrophage immunometabolic reprogramming are key steps underlying their mode of action. These findings have significant implications for the development of MSC potency assays and biomanufacturing for clinical translation.

2021-09-16 | GSE156240 | GEO

Mesenchymal stromal cell (MSC) Metabolite MS study

Project description:Metabolomics and lipidomics workflows were used to analyze Mesenchymal stromal cell (MSC) metabolites. Metabolite abundances were used to model MSC potency results in IDO and T-cell proliferation assays.

2023-02-07 | ST002469 | MetabolomicsWorkbench

Mesenchymal stromal cell apoptosis is required for their therapeutic function.

Project description:Multipotent mesenchymal stromal cells (MSCs) ameliorate a wide range of diseases in preclinical models, but the lack of clarity around their mechanisms of action has impeded their clinical utility. The therapeutic effects of MSCs are often attributed to bioactive molecules secreted by viable MSCs. However, we found that MSCs underwent apoptosis in the lung after intravenous administration, even in the absence of host cytotoxic or alloreactive cells. Deletion of the apoptotic effectors BAK and BAX prevented MSC death and attenuated their immunosuppressive effects in disease models used to define MSC potency. Mechanistically, apoptosis of MSCs and their efferocytosis induced changes in metabolic and inflammatory pathways in alveolar macrophages to effect immunosuppression and reduce disease severity. Our data reveal a mode of action whereby the host response to dying MSCs is key to their therapeutic effects; findings that have broad implications for the effective translation of cell-based therapies.

| S-EPMC8586224 | biostudies-literature

Menstrual blood derived mesenchymal stromal cells

Project description:Mesenchymal stromal cells (MSCs) have been shown to exert their therapeutic effects through the secretion of various paracrine factors, including extracellular vesicles (EVs). These EVs are now being developed as a promising alternative to cell-based therapies. Menstrual blood-derived stromal cells (MenSCs) are a type of MSC that have emerged as a innovative source due to their immunomodulatory and regenerative properties. Additionally, new strategies of cell priming could potentially alter the concentration and cargo of released EVs, leading to modifications in their biological properties. In this study, we aimed to characterize the EVs released by MenSCs and to compare their therapeutic potential under three different preconditioning conditions (proinflammatory stimuli, physioxia, and acute hypoxia).

2023-04-05 | MSV000091644 | MassIVE

Nuclear receptors Nur77 and Nurr1 modulate mesenchymal stromal cell migration

Project description:Expression analysis of migrating and non-migrating mesenchymal stromal cells (MSC) in fetal bone marrow Keywords: fetal bone marrow, mesenchymal stromal cells, migration, gene expression, genomics Three biological replates for both migrating and non-migrating mesenchymal stromal cells (MSC) in fetal bone marrow

2011-10-23 | E-GEOD-24892 | biostudies-arrayexpress

Cultured human amniotic fluid-derived mesenchymal stromal cells

Project description:This SuperSeries is composed of the following subset Series: GSE30064: Cultured human amniotic fluid-derived mesenchymal stromal cells [PIQOR data] GSE30065: Cultured human amniotic fluid-derived mesenchymal stromal cells [miRXplore data] Refer to individual Series

2011-06-18 | E-GEOD-30066 | biostudies-arrayexpress

Vessel Forming Mesenchymal Stromal Cell Populations

Project description:Vessel Forming Mesenchymal Stromal Cell Populations

| PRJNA750935 | ENA

Single-cell sequencing of adipose-derived mesenchymal stromal cells and dermal fibroblasts

Project description:Single-cell sequencing of adipose-derived mesenchymal stromal cells and fibroblasts.

| EGAS00001006954 | EGA

A mesoderm-derived mesenchymal stem/stromal cells (MSC) precursor

Project description:This SuperSeries is composed of the following subset Series: GSE20045: A mesoderm-derived mesenchymal stem/stromal cells (MSC) precursor: time course experiment GSE20046: A mesoderm-derived mesenchymal stem/stromal cells (MSC) precursor: stages of development experiment Refer to individual Series

2010-12-03 | E-GEOD-20047 | biostudies-arrayexpress

Diabetic microenvironment deteriorates the regenerative capacities of adipose mesenchymal stromal cells

Project description:Human adipose mesenchymal stromal cells cutltured in culture media containing diabetic patient serum or normal indvidual serum as control for 6 days and 1 month period

2024-06-22 | PXD036116 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data